<unk>  is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) that is FDA approved for the treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype (indicated for add-on maintenance treatment).   Common adverse reactions include headache, injection site reaction, back pain, and fatigue (5%).
Mepolizumab
Vedolizumab
Certolizumab pegol
Natalizumab
Belatacept
Reslizumab
Eculizumab
Emicizumab